NO20063036L - Farmasoytiske preparater omfattende lercanidipine - Google Patents

Farmasoytiske preparater omfattende lercanidipine

Info

Publication number
NO20063036L
NO20063036L NO20063036A NO20063036A NO20063036L NO 20063036 L NO20063036 L NO 20063036L NO 20063036 A NO20063036 A NO 20063036A NO 20063036 A NO20063036 A NO 20063036A NO 20063036 L NO20063036 L NO 20063036L
Authority
NO
Norway
Prior art keywords
lercanidipine
pharmaceutical preparations
delayed
dispersed
pharmaceutical composition
Prior art date
Application number
NO20063036A
Other languages
English (en)
Other versions
NO340114B1 (no
Inventor
Per Holm
Thomas Norling
Original Assignee
Lifecycle Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifecycle Pharma As filed Critical Lifecycle Pharma As
Publication of NO20063036L publication Critical patent/NO20063036L/no
Publication of NO340114B1 publication Critical patent/NO340114B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Et farmasøytisk preparat for kontrollert frigjøring omfattende lerkanidipin oppløst eller dispergert i et fast bærestoff ved romtemperatur, slik at det oppnås en fast dispersjon, gir forsinket frigjøring av lerkanidipin over et forlenget tidsrom, reduserte mateffekten og ga forhøyet biotilgjengelighet, sammenlignet med kommersielt tilgjengelige lerkanidipinholdige produkter.
NO20063036A 2003-12-01 2006-06-29 Farmasøytiske preparater omfattende lercanidipine NO340114B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301778 2003-12-01
DKPA200400249 2004-02-18
US55378704P 2004-03-16 2004-03-16
PCT/DK2004/000836 WO2005053689A2 (en) 2003-12-01 2004-12-01 Pharmaceutical compositions comprising lercanidipine

Publications (2)

Publication Number Publication Date
NO20063036L true NO20063036L (no) 2006-09-01
NO340114B1 NO340114B1 (no) 2017-03-13

Family

ID=34657505

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063036A NO340114B1 (no) 2003-12-01 2006-06-29 Farmasøytiske preparater omfattende lercanidipine

Country Status (14)

Country Link
US (1) US20070105912A1 (no)
EP (1) EP1694305B1 (no)
JP (1) JP2007512265A (no)
KR (1) KR20060125824A (no)
AU (1) AU2004294674B2 (no)
BR (1) BRPI0417043A (no)
CA (1) CA2547657A1 (no)
DE (1) DE04801160T1 (no)
EA (1) EA013426B1 (no)
ES (1) ES2281313T3 (no)
IL (1) IL175973A (no)
MX (1) MXPA06006118A (no)
NO (1) NO340114B1 (no)
WO (1) WO2005053689A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014249B1 (ru) * 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
ES2953390T3 (es) 2006-08-31 2023-11-10 Adare Pharmaceuticals Inc Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
RU2341262C1 (ru) * 2007-07-09 2008-12-20 Илья Николаевич Медведев Способ коррекции ослабления функций стенки сосудов при метаболическом синдроме
NZ582648A (en) * 2007-07-23 2012-06-29 Pharmathen Sa Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
AR072477A1 (es) * 2008-07-11 2010-09-01 Solvay Pharm Bv Formulacion farmaceutica de eprosartan. uso.
US20100209348A1 (en) * 2009-02-18 2010-08-19 Arondo Pharma, Inc. Methods for determining liposome bioequivalence
RU2013108256A (ru) * 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
UY33772A (es) * 2010-12-09 2012-07-31 Lg Life Sciences Ltd Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma.
WO2012085249A2 (en) * 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
EP2943223B1 (en) * 2013-01-14 2020-08-19 InFirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
JP2017533970A (ja) * 2014-11-11 2017-11-16 ヴァーデュア サイエンスィズ 加齢性疾患に対する脂溶性化合物の改善されたバイオアベイラビリティーに対する安定な固体脂質粒子組成物
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
WO2019204502A1 (en) * 2018-04-17 2019-10-24 Poviva Tea, Llc Lipophilic active agent infused compositions with reduced food effect
CN112716903B (zh) * 2021-01-18 2023-03-21 广州一品红制药有限公司 一种氨氯地平干混悬剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011726A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US20030180355A1 (en) * 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension

Also Published As

Publication number Publication date
IL175973A0 (en) 2006-10-05
AU2004294674A1 (en) 2005-06-16
EA013426B1 (ru) 2010-04-30
CA2547657A1 (en) 2005-06-16
EA200601075A1 (ru) 2006-12-29
US20070105912A1 (en) 2007-05-10
WO2005053689A3 (en) 2006-04-27
JP2007512265A (ja) 2007-05-17
NO340114B1 (no) 2017-03-13
BRPI0417043A (pt) 2007-02-06
ES2281313T3 (es) 2020-07-24
ES2281313T1 (es) 2007-10-01
AU2004294674B2 (en) 2009-02-26
KR20060125824A (ko) 2006-12-06
IL175973A (en) 2016-03-31
WO2005053689A2 (en) 2005-06-16
MXPA06006118A (es) 2006-08-11
EP1694305A2 (en) 2006-08-30
EP1694305B1 (en) 2019-10-16
DE04801160T1 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
NO20063036L (no) Farmasoytiske preparater omfattende lercanidipine
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
NO20062508L (no) Administrering av levodopa og karbidopa
AU2003270255A1 (en) Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve
NO20081910L (no) Selektive Y2-reseptoragonister for terapeutiske intervensjoner
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
ATE428310T1 (de) Zusammensetzungen enthaltend zuckerrüben pektin und carotinoide
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
DK1498039T3 (da) Vitale cellepræparater, som indeholder mælkesyrebakterie som aktivt stof, og mælkesyrebakterieholdige fødevareprodukter
NO20090458L (no) Sukkerfrie, lagringsstabile antihistaminsaftpreparater
DK1414816T3 (da) Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling
ATE531274T1 (de) Pulverförmige zusammensetzungen von fettlöslichen substanzen
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
PL375411A1 (en) Pharmaceuticals formulations and methods for modified release of statin drugs
NO20044156L (no) Nye 1,2,3-substituerte indolizinderivater, inhibitorer av FGF`er, fremgangsmate for fremstilling av de samme, og farmasoytiske preparater inneholdende de samme
HUP0401499A3 (en) Indole derivatives as cox ii inhibitors, process for their preparation and pharmaceutical compositions containing them
NO20051654L (no) Forlenget frigjoring av farmasoytisk preparat
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
EA200702594A1 (ru) Многофункциональные композиции концентрата с высоким содержанием действующего вещества для контроля эктопаразитов
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
GEP20125636B (en) Slow-release formulation based on glycogen and alginate association
UA89177C2 (ru) Фармацевтическая композиция с контролируемым высвобождением, которая содержит лерканидипин

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees